# Crinetics Pharmaceuticals, Inc. (CRNX) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_1f37359aab2a58050762 · retrieved 2026-08-11T16:13:53.535Z

## Overview
Crinetics Pharmaceuticals is a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, with its first commercial product PALSONIFY (paltusotine) approved for treatment of acromegaly.

On July 6, 2026, Vertex Pharmaceuticals Incorporated announced a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close in the third quarter of 2026, subject to customary closing conditions including regulatory approvals and Crinetics stockholder approval.

## Terms
- Counterparty: Vertex Pharmaceuticals Incorporated · Deal value: $10.00B · Consideration: cash · Price/share: $85

## Key dates
- Announced 2026-07-10 · Expected close 2026-09-30

## Timeline
- 2026-07-10 · 8-K (0001140361-26-028208): 8-K - Crinetics Pharmaceuticals, Inc. — *Crinetics Pharmaceuticals, Inc. is a pharmaceutical company developing drug candidates; the filing does not provide detailed business description.* Crinetics Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger dated July 6, 2026 with Vertex Pharmaceuticals Incorporated (Parent) and Clark Merger Sub, Inc., a wholly owned subsidiary of Parent. Pursuant to the merger agreement, Merger Sub will merge with and into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. The filing does not disclose the total transaction value or per-share consideration. The company also entered into Non-Compete Agreements with certain key employees (R. Scott Struthers, Tobin Schilke, Stephen Betz, and Isabel Kalofonos) effective upon the Merger Closing Date, with cash payments to Schilke ($140,000), Betz ($30,000), and Kalofonos ($30,000) for their non-compete obligations.
  https://www.sec.gov/Archives/edgar/data/1658247/0001140361-26-028208.txt
- 2026-08-03 · 8-K (0001658247-26-000052): 8-K - Crinetics Pharmaceuticals, Inc. — *Crinetics Pharmaceuticals is a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, with its first commercial product PALSONIFY (paltusotine) approved for treatment of acromegaly.* On July 6, 2026, Vertex Pharmaceuticals Incorporated announced a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close in the third quarter of 2026, subject to customary closing conditions including regulatory approvals and Crinetics stockholder approval.
  https://www.sec.gov/Archives/edgar/data/1658247/0001658247-26-000052.txt

## Citations
- 0001140361-26-028208 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126028208
- 0001658247-26-000052 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000165824726000052